Cargando…
Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
OBJECTIVE: We investigated the efficacy and safety of carfilzomib‐containing induction before salvage high‐dose melphalan with autologous stem‐cell transplantation (salvage ASCT) and maintenance with carfilzomib and dexamethasone after salvage ASCT in multiple myeloma. METHODS: This randomised, open...
Autores principales: | Gregersen, Henrik, Peceliunas, Valdas, Remes, Kari, Schjesvold, Fredrik, Abildgaard, Niels, Nahi, Hareth, Andersen, Niels Frost, Vangsted, Annette Juul, Klausen, Tobias Wirenfeldt, Helleberg, Carsten, Carlson, Kristina, Frølund, Ulf Christian, Axelsson, Per, Stromberg, Olga, Blimark, Cecilie Hveding, Crafoord, Jacob, Tsykunova, Galina, Eshoj, Henrik Rode, Waage, Anders, Hansson, Markus, Gulbrandsen, Nina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292771/ https://www.ncbi.nlm.nih.gov/pubmed/34536308 http://dx.doi.org/10.1111/ejh.13709 |
Ejemplares similares
-
P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA
por: Nielsen, Lene Kongsgaard, et al.
Publicado: (2023) -
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study
por: Gregersen, Henrik, et al.
Publicado: (2017) -
Potential value of pre-planned imaging of bone disease in multiple myeloma
por: Gundesen, Michael T., et al.
Publicado: (2023) -
P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.
por: Gundesen, Michael, et al.
Publicado: (2023) -
The Danish National Multiple Myeloma Registry
por: Gimsing, Peter, et al.
Publicado: (2016)